Manulife Singapore has teamed up with Guardant Health to improve access to the cutting-edge Guardant360 liquid biopsy test for eligible customers with advanced solid tumour cancers. This landmark collaboration represents a significant step in advancing cancer care in Singapore, offering patients access to personalised treatment options that may enhance clinical outcomes.
The Guardant360 liquid biopsy test provides comprehensive genomic profiling for all advanced solid tumours. It offers critical genomic and epigenomic insights from a simple blood draw, delivering results within just seven days of lab sample receipt. This non-invasive test is especially valuable for patients who lack sufficient tumour tissue for traditional biopsies, helping oncologists quickly identify appropriate treatments.
While specific eligibility criteria and program details will be announced later, this initiative promises to provide Manulife customers with broader access to guideline-recommended biomarkers across all solid cancers.
